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Introduction
A congenital giant left atrial appendage (LAA) is a rare
condition only described in case reports [1]. Supraventric-
ular tachycardias, including atrial fibrillation (AF), and
systemic embolisation are the most common clinical
findings [1, 2]. Almost all reported cases are treated by
resection of the giant LAA [1]. A few cases are treated
conservatively [3, 4]. Catheter ablation has not been
reported as a treatment option. For the first time, we
present a patient with paroxysmal AF and a congenital
giant LAA who was successfully treated by percutaneous
pulmonary vein antrum isolation (PVAI).
Case
A 42-year-old man with drug-refractory AF was referred to
our cardiology outpatient clinic to discuss treatment options.
Echocardiography and magnetic resonance imaging (MRI)
had been performed in the referring hospital which had
revealed a giant LAA. No other abnormalities were reported.
The main complaint of the patient was recurrent,
nocturnal episodes of AF once a week. His medical history
was unremarkable. Physical examination revealed no
abnormalities and electrocardiography showed sinus
rhythm without signs of left atrial enlargement. The chest
radiograph showed a prominent left upper cardiac border
but with a normal cardiothoracic ratio. Sotalol, and later
amiodarone, flecainide and disopyramide were tried but
were ineffective or resulted in unpleasant side effects.
Since medical therapy was no option, alternative treat-
ments were discussed. The role of the giant LAA in the
pathophysiology of AF is unclear. Therefore, we proposed
to perform PVAI by radiofrequency catheter ablation
leaving the giant LAA in situ. The patient gave his consent.
In preparation for PVAI, transoesophageal echocardiog-
raphy was performed which showed a giant LAAwith good
flow velocity of >40 cm/s (Fig. 1). No thrombi were seen.
MRI was repeated and revealed the giant LAA with a
length of 7 cm in the coronal view (Figs. 2 and 3).
PVAI was performed by encircling right and left
pulmonary vein antrums in pairs using an irrigated 4 mm
electrode with a maximum electrode temperature of 43°C
and a power of 30–40 W. The procedure lasted 240 min and
the endpoint was successful electrical isolation of all
pulmonary veins. Total fluoroscopy dose was 104 mGy
and total fluoroscopy time was 27 min. The course of the
procedure was uneventful.
After PVAI the patient was seen at the outpatient clinic.
Antiarrhythmic medication was discontinued after 3 months.
Six months after ablation the patient experienced a single
episode of AF, treated with electrical cardioversion. With
the exception of this event no recurrences of AF were seen,
confirmed by four 48-hour Holter recordings (5, 7, 12, and
16 months following PVAI). Seventeen months after PVAI
the patient is still in sinus rhythm and asymptomatic. He
will continue to take oral anticoagulation.
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A giant LAA is a rare condition that can be acquired or
congenital when it presents as an isolated anomaly, as was
the case in our patient [5, 6]. The patient has a monozygotic
twin brother who also underwent MRI; however, no
abnormalities were seen.
Approximately 80 case reports were identified by Chowd-
hury et al. that describe an aneurysm of the LAA [1]. Almost
all known cases are treated by resection of the LAA and it is
advised in the literature to perform this treatment even in
asymptomatic patients to prevent AF and thromboembolic
events [1, 2, 7, 8]. However, a role of the giant LAA as a
substrate of AF has never been demonstrated and no large
trials have been performed to test the efficacy of resection of
a giant LAA in patients with AF. Mathur et al. performed an
electrophysiological study in a patient with a giant LAA
presenting with AF and found arrhythmic foci in both atria
quickly degenerating into AF [9]. They decided to perform a
Cox-Maze III procedure in addition to LAA resection since
they hypothesised that the trigger of AF may not be located
in the giant LAA itself. One year post-operatively this patient
was still in sinus rhythm. Therefore, on the grounds of the
present literature, the role of the giant LAA in the aetiology
of AF is unknown.
In 1998 Haissaguerre et al. identified pulmonary vein
triggers as a principal mechanism of AF initiation and
perpetuation [10]. Since then, electrical isolation of the
Fig. 3 Three-dimensional reconstruction with magnetic resonance
imaging showing the left atrium with the giant left atrial appendage
from left posterior. LAA = left atrial appendage
Fig. 2 Magnetic resonance imaging of the heart in oblique coronal
view demonstrating the giant left atrial appendage with a length of
68 mm. LA = left atrium, LAA = left atrial appendage, LV = left
ventricle
Fig. 1 Transoesophageal echo-
cardiogram showing the giant
left atrial appendage. LA = left
atrium, LAA = left atrial
appendage, LV = left ventricle,
MV = mitral valve
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treatment of choice in patients with AF [11]. Since our
patient had typically paroxysmal AF with normal left atrial
size we hypothesised that the trigger for AF may be located
in the pulmonary veins and not in the LAA. Therefore, we
decided to perform PVAI without resection of the LAA. With
the exception of one episode, this patient had no recurrences
of AF while off antiarrhythmic drugs 17 months after the
procedure, providing evidence for a pulmonary vein trigger.
Conclusion
This case report describes a patient with a congenital giant
LAA presenting with typically vagally induced paroxysmal
AF. We have shown that this patient can be successfully
treated with PVAI without resection of the LAA.
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